MDS Clinical Trials
Here are the 6 most popular medical studies for mds
Alkylating agents
Cyclophosphamide +7 More for Leukemia
This trial is studying four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant to see how well they work in treating patients with relapsed or refractory hematologic cancer.
Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
Chemotherapy
CFI-400945 Fumarate for Acute Myeloid Leukemia
This trial is testing an investigational drug to treat relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome. The goal is to find the best dose that is safe and tolerable for patients.
Alkylating agents
IM-TMI + Chemotherapy for AML and MDS
This trial is testing whether adding a new kind of radiation to the standard myeloablative fludarabine/ i.v. targeted busulfan conditioning improves outcomes for patients receiving allogeneic hematopoietic stem cell transplant (HSCT).
Popular filter options for mds trials
MDS Clinical Trials
View 89 MDS medical studies.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Myelomonocytic Leukemia Clinical Trials
View 89 Myelomonocytic Leukemia medical studies.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
HLA Positive Clinical Trials
View 8 HLA positive medical studies.
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
HLA-A Positive Clinical Trials
View 8 HLA-A positive medical studies.
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
Phase 3 Myelodysplastic Syndrome Clinical Trials
View 89 phase 3 myelodysplastic syndrome medical studies.
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Monoclonal Antibodies
MBG453 + Azacitidine for Myelodysplastic Syndrome
This trial is a Phase III, randomized, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome or Chronic Myelomonocytic Leukemia-2.
Anti-metabolites
Cedazuridine + Azacitidine for Leukemia
This trial is designed to test a new treatment for leukemia that is taken orally. The first phase will test different doses to find the best one. The second phase will compare the new treatment to the standard one given by injection. The third phase will test the best oral dose against the standard injection dose.
Myelodysplastic Syndrome Clinical Trials With No Placebo
View 89 myelodysplastic syndrome medical studies that do not have a placebo group.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
View More Mds Trials
See another 66 medical studies focused on mds.
Frequently Asked Questions
Introduction to mds
What are the top hospitals conducting mds research?
When it comes to cutting-edge clinical trials in the field of myelodysplastic syndromes (MDS), several top hospitals are making significant strides. In Boston, the Dana Farber Cancer Institute leads the way with an impressive 13 active MDS trials and a commendable history of 42 completed studies since their first recorded trial in 2001. Another institution contributing to advancements in MDS research is Massachusetts General Hospital, also located in Boston. They currently have seven ongoing MDS trials and have conducted a remarkable total of 47 trials dating back to their earliest recorded trial in 1984.
Moving southwards to Miami, we find the University of Miami playing an important role by conducting seven active clinical trials for MDS while accumulating experience from sixteen previously held investigations since initiating their first trial on this condition just fifteen years ago, in 2006.
Meanwhile, Washington University School of Medicine takes center stage as one of the leading institutions researching MDS. With six current clinical trials focused on this condition and a robust track record consisting of forty-one completed studies since they started recording data for these types of cases around eighteen years ago(way back till2003).
Finally rounding out our list is Fred Hutchinson Cancer Research Center situated amidst Seattle's vibrant medical community; despite a smaller number compared to other establishments mentioned so far still undeniably contribute significantly towards understanding Myelodysplastic Syndromes better.With six ongoing clinical tests under its belt combined with eighty-five previous experiments spanning three decades(making them one among most experienced) marking pivotal starting point exactly thirty years ago during1991
These esteemed hospitals represent beacons of hope for those affected by MDS worldwide. Through groundbreaking research and innovative approaches, each step taken brings us closer to more effective treatments and improved outcomes for patients living with this complex blood disorder.
Which are the best cities for mds clinical trials?
When it comes to MDS (myelodysplastic syndromes) clinical trials, several cities emerge as leading hubs for research and innovation. Among them are Boston, Massachusetts, with 36 active trials investigating treatments like H3B-8800 (RVT-2001), Venetoclax, and Inqovi. Houston, Texas follows closely behind with 27 ongoing studies exploring therapies such as BGB-11417 and CC-95251. New york, New York is also a prominent city for MDS clinical trials with 20 active studies focusing on interventions like Bone Marrow Hematopoietic Stem Cell Transplantation and Oral Azacitidine. These cities offer individuals battling MDS the opportunity to participate in cutting-edge trials that may pave the way for improved treatment options and better outcomes.
Which are the top treatments for mds being explored in clinical trials?
Exciting advancements are taking place in the realm of MDS treatment, with several leading contenders emerging from ongoing clinical trials. One such contender is CPX-351, currently being explored in two active trials for MDS. Since its introduction in 2009, it has been involved in a total of 11 trials aiming to combat this condition. Another promising option on the horizon is luspatercept, which also boasts two active trials and has participated in a total of 15 MDS studies since its listing in 2016. Additionally, MBG453 and Atorvastatin show great potential as they both are engaged in two ongoing MDS trials each. As researchers delve deeper into these treatments' effectiveness and safety profiles, hope continues to grow for patients battling MDS worldwide
What are the most recent clinical trials for mds?
Recent clinical trials for MDS offer promising prospects in the field of hematologic disorders. Sitagliptin, Bortezomib, and Cyclophosphamide have demonstrated potential as a combined therapy for MDS patients. Another trial explores CD34+ Peripheral Blood Progenitor Cell Transplantation using Busulfan/Melphalan/Fludarabine regimen to improve outcomes in MDS cases. Itacitinib is also being investigated as a potential treatment option for this condition. Additionally, the use of Cy/Flu/TBI along with post-transplant CY shows promise in addressing MDS-related challenges. These ongoing trials shed light on new possibilities that may enhance the lives of individuals affected by MDS.
What mds clinical trials were recently completed?
In recent years, several clinical trials exploring potential treatments for MDS (myelodysplastic syndromes) have concluded, showcasing advancements in this field. Noteworthy completed trials include the investigation of Lemzoparlimab by AbbVie in June 2021, the evaluation of sabatolimab by Novartis Pharmaceuticals in May 2021, and a study on Azacitidine sponsored by Pfizer that also concluded in May 2021. These milestones highlight the ongoing efforts to find effective therapies for MDS and provide hope for patients affected by this condition.